Indeed, it has been shown that long-term, low-dose IL-2 therapy preferentially stimulates Treg cells due to their constitutive high expression of trimeric IL-2R and can be used for treatment of autoimmune diseases and delaying allograft rejection (Klatzmann and Abbas, 2015; Yu et al., 2009). Here, IL2 is linked to autoimmune disease.